N(α)-(p-Toluolsulfonyl)-L-ornithin | 19595-40-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N(α)-(p-Toluolsulfonyl)-L-ornithin
• 英文别名: N^α-Tosyl-D-ornithine；N²-(toluene-4-sulfonyl)-L-ornithine；N²-(Toluol-4-sulfonyl)-L-ornithin；N^α-(Toluol-sulfonyl-(4))-L-ornithin；(2S)-5-amino-2-[(4-methylphenyl)sulfonylamino]pentanoic acid
• CAS: 19595-40-5
• 化学式: C₁₂H₁₈N₂O₄S
• 分子量: 286.352
• InChiKey: HAXKLVLZQHPSPK-NSHDSACASA-N

物化性质

• 熔点：
  186-188 °C (decomp)
• 沸点：
  495.6±55.0 °C(Predicted)
• 密度：
  1.295±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N(α)-(p-Toluolsulfonyl)-L-ornithin 在 氢溴酸 、 溶剂黄146 作用下， 生成 L-鸟氨酸
  参考文献：
  名称：

  Zaoral; Rudinger, Collection of Czechoslovak Chemical Communications, 1959, vol. 24, p. 1993,2002

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(甲苯-4-磺酰基)-L-谷氨酸-5-腈 在 盐酸 、 溶剂黄146 、 铂 作用下， 生成 N(α)-(p-Toluolsulfonyl)-L-ornithin
  参考文献：
  名称：

  Zaoral; Rudinger, Collection of Czechoslovak Chemical Communications, 1959, vol. 24, p. 1993,2002

  摘要：

  DOI：

文献信息

• 973. The formation of cyclic lactams from derivatives of basic amino-acids
  作者：B. C. Barrass、D. T. Elmore

  DOI：10.1039/jr9570004830

  日期：——
• Physician versus Computer Knowledge of Potential Drug Interactions in the Emergency Department
  作者：Mark I. Langdorf、John C. Fox、Rakesh S. Marwah、Brian J. Montague、Michael M. Hart

  DOI：10.1111/j.1553-2712.2000.tb00483.x

  日期：2000.11

  Abstract. Introduction: Proliferation of Food and Drug Administration—approved drugs makes it impossible for emergency medicine (EM) faculty to stay current on potential interactions between drugs, and with diseases, laboratory tests, and ethanol. A computer database may augment physician knowledge. Objectives: To compare the performance of EM faculty and an “expert” emergency physician (EP) with that of a criterion standard computer database in identifying potential drug interactions, and to report the incidence of drug—ethanol and drug—laboratory test interactions. Methods: This was a retrospective review of 276 emergency department charts for drug, ethanol, lab, and medical history. Evaluation by both EM faculty and an “expert” EP of patient history was done to identify potential interactions, and comparison with the Micromedex Drug‐Reax database for potential interactions (graded minor, moderate, or major) was made. Clinical significance of potential interactions was judged by a second EM faculty member. Results: Seventeen percent of the patients had potential drug—drug interactions, and 25% of these were judged to be clinically significant. Up to 52% of the patients had potential drug—ethanol interactions, while 38% of the patients could have potential drug—lab interactions. Sensitivity, specificity, and positive and negative predictive values of the EM faculty for potential drug—drug interactions compared with the computer were poor, at 14%, 58%, 6%, and 23%, respectively. The corresponding values for the “expert” EP were 25%, 86%, 26%, and 85%. The “expert” EP was statistically better than the EM faculty, but still less sensitive and predictive than the computer. Conclusions: A computer can aid the physician in avoiding potential drug interactions. Prospective validation of these findings should be done.
• Poduska,K. et al., Collection of Czechoslovak Chemical Communications, 1965, vol. 30, p. 2410 - 2433
  作者：Poduska,K. et al.

  DOI：——

  日期：——
• [EN] CELL PERMEABLE INHIBITORS OF ANAPHASE PROMOTING COMPLEX<br/>[FR] INHIBITEURS DU COMPLEXE DE PROMOTION DE L'ANAPHASE POUVANT PÉNÉTRER DANS DES CELLULES
  申请人：HARVARD COLLEGE

  公开号：WO2012031118A2

  公开（公告）日：2012-03-08

  The invention provides compositions and methods for treating cell cycle disorders. Compositions of the invention include proTAME, a prodrug analog of TAME, and, optionally, one or more therapeutic agents.
• Zaoral; Rudinger, Collection of Czechoslovak Chemical Communications, 1959, vol. 24, p. 1993,2002
  作者：Zaoral、Rudinger

  DOI：——

  日期：——